- Home
- IONS vs CALM Comparison
IONS vs CALM Comparison
Compare IONS & CALM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CALM
- Stock Information
- Founded
- IONS 1989
- CALM 1957
- Country
- IONS United States
- CALM United States
- Employees
- IONS N/A
- CALM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CALM Farming/Seeds/Milling
- Sector
- IONS Health Care
- CALM Consumer Staples
- Exchange
- IONS Nasdaq
- CALM Nasdaq
- Market Cap
- IONS 4.6B
- CALM 4.5B
- IPO Year
- IONS 1991
- CALM 1996
- Fundamental
- Price
- IONS $32.26
- CALM $91.23
- Analyst Decision
- IONS Buy
- CALM Sell
- Analyst Count
- IONS 18
- CALM 3
- Target Price
- IONS $57.41
- CALM $83.00
- AVG Volume (30 Days)
- IONS 1.7M
- CALM 1.1M
- Earning Date
- IONS 04-30-2025
- CALM 04-08-2025
- Dividend Yield
- IONS N/A
- CALM 7.35%
- EPS Growth
- IONS N/A
- CALM 258.93
- EPS
- IONS N/A
- CALM 20.24
- Revenue
- IONS $717,253,000.00
- CALM $3,799,016,000.00
- Revenue This Year
- IONS N/A
- CALM $77.09
- Revenue Next Year
- IONS $27.39
- CALM N/A
- P/E Ratio
- IONS N/A
- CALM $4.53
- Revenue Growth
- IONS N/A
- CALM 60.00
- 52 Week Low
- IONS $23.95
- CALM $56.74
- 52 Week High
- IONS $52.34
- CALM $116.41
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- CALM 45.58
- Support Level
- IONS $31.66
- CALM $91.42
- Resistance Level
- IONS $33.98
- CALM $97.49
- Average True Range (ATR)
- IONS 1.30
- CALM 3.09
- MACD
- IONS 0.41
- CALM -0.31
- Stochastic Oscillator
- IONS 68.84
- CALM 15.63
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CALM Cal-Maine Foods Inc.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.